Latest Conference Articles

Zytiga and Prednisone Plus Erleada Reduces Risk of Disease Progression in Prostate Cancer Subtype

Zytiga and Prednisone Plus Erleada Reduces Risk of Disease Progression in Prostate Cancer Subtype

February 12th 2021, 8:45pm

ASCO Genitourinary Symposium

The combination of Erleada, Zytiga and the steroid prednisone was associated with a trend toward better survival outcomes in certain patients with chemotherapy-naive metastatic castration-resistant prostate cancer.

Opdivo-Cabometyx Combo Improves Quality of Life in Kidney Cancer Subtype

Opdivo-Cabometyx Combo Improves Quality of Life in Kidney Cancer Subtype

February 12th 2021, 6:30pm

ASCO Genitourinary Symposium

Front-line treatment with Opdivo plus Cabometyx improved health-related quality of life outcomes in patients with advanced renal cell carcinoma.

Front-Line Immunotherapy Improves Survival in Kidney Cancer Subtype, Versus Certain Targeted Therapies

Front-Line Immunotherapy Improves Survival in Kidney Cancer Subtype, Versus Certain Targeted Therapies

February 11th 2021, 9:56pm

ASCO Genitourinary Symposium

Patients with metastatic non–clear cell renal cell carcinoma who receive immune checkpoint inhibitor–based regimens as a first treatment option may have improved survival, versus those who receive select targeted therapies.

Starting Treatment With Lenvima at a Higher Dose Improves Quality of Life and Symptom Control in Type of Kidney Cancer

Starting Treatment With Lenvima at a Higher Dose Improves Quality of Life and Symptom Control in Type of Kidney Cancer

February 11th 2021, 8:49pm

ASCO Genitourinary Symposium

A higher starting dose of Lenvima, compared with a lower starting dose, prolonged the time that patients with renal cell carcinoma experienced negative effects on factors including social and physical functioning, financial difficulties and cogitative functioning over time.

New Combination Could Prove Beneficial After Immunotherapy in Patients with Clear Cell RCC

New Combination Could Prove Beneficial After Immunotherapy in Patients with Clear Cell RCC

February 11th 2021, 6:59pm

ASCO Genitourinary Symposium

The combination of Lenvima plus everolimus was found to be an acceptable treatment option for patients who have previously received immunotherapy for clear cell renal cell carcinoma, according to the findings of an exploratory analysis of a phase 2 trial presented virtually at the 2021 ASCO Genitourinary Cancers Symposium.

Early Use of Fixed-Duration Venclexta-Rituxan Combo in Patients with Relapsed/Refractory CLL Effective, And Does Not Compromise Subsequent Therapy Response in Patients Who Need Retreatment

Early Use of Fixed-Duration Venclexta-Rituxan Combo in Patients with Relapsed/Refractory CLL Effective, And Does Not Compromise Subsequent Therapy Response in Patients Who Need Retreatment

December 14th 2020, 4:00pm

American Society of Hematology Annual Meeting

More than half of the patients (66.7%) in the Venclexta and Rituxan arm who went on to receive subsequent Venclexta-based treatments experienced a partial response or partial nodal response to the therapy.

Patients Who Experienced Chemotherapy-Induced Nausea/Vomiting During First Cycle of Cancer Treatment May Be at Greater Risk for Recurrence of the Side Effect

Patients Who Experienced Chemotherapy-Induced Nausea/Vomiting During First Cycle of Cancer Treatment May Be at Greater Risk for Recurrence of the Side Effect

December 12th 2020, 7:00pm

SABCS

Approximately half of the patients with breast cancer who failed anti-nausea or vomiting therapy for chemotherapy-induced nausea/vomiting during their first cycle of treatment failed to avoid the side effect at some point during the next three treatment cycles.

Tesetaxel with Reduced Dose of Xeloda Improves Progression-Free Survival in Breast Cancer

Tesetaxel with Reduced Dose of Xeloda Improves Progression-Free Survival in Breast Cancer

December 12th 2020, 4:00pm

SABCS

Tesetaxel, a novel agent, with Xeloda contributed to a median progression-free survival of 9.8 months, compared with 6.9 months with Xeloda alone, in patients with metastatic breast cancer.

Side Effects from Oral Paclitaxel Plus Encequidar May Be Mitigated with Anti-Nausea Medications, Loperamide

Side Effects from Oral Paclitaxel Plus Encequidar May Be Mitigated with Anti-Nausea Medications, Loperamide

December 11th 2020, 9:30pm

SABCS

An increase in gastrointestinal side effects were found with the more effective combination of oral paclitaxel and encequidar; however, new safety evaluations demonstrated that various antiemetics can help treat these effects in patients with metastatic breast cancer.

Treatment with Imbruvica and Rituxan May Benefit Patients with Waldenstrom’s Macroglobulinemia Out to 5 Years

Treatment with Imbruvica and Rituxan May Benefit Patients with Waldenstrom’s Macroglobulinemia Out to 5 Years

December 6th 2020, 7:30pm

American Society of Hematology Annual Meeting

The benefit observed in patients with Waldenstrom’s macroglobulinemia treated with Imbruvica (ibrutinib) plus Rituxan (rituximab), compared with placebo and Rituxan, focused on survival and response to the treatment, both of which occurred despite prior treatment and genotypes.

Interventions Improve Survival, Quality of Life for Patients Experiencing Financial Toxicity

Interventions Improve Survival, Quality of Life for Patients Experiencing Financial Toxicity

December 6th 2020, 7:00pm

American Society of Hematology Annual Meeting

Dr. Knight presents findings that suggest financial intervention can improve mortality rate in patients with hematologic malignancy at the 2020 ASH Meeting.

Venclexta-Rituxan Combo Continues to Show Survival Benefit Through 5 Years in Relapsed/Refractory CLL

Venclexta-Rituxan Combo Continues to Show Survival Benefit Through 5 Years in Relapsed/Refractory CLL

December 5th 2020, 9:33pm

American Society of Hematology Annual Meeting

Compared with patients assigned bendamustine with Rituxan, those assigned Venclexta with Rituxan maintained an overall survival benefit, with a five-year OS estimate of 82.1% for the Venclexta with Rituxan group vs. 62.2% for the bendamustine with Rituxan group.

Data Support Fixed-Treatment Duration of Imbruvica/Venclexta Combo Could Lead to Treatment Discontinuation in Certain Patients With CLL/SLL

Data Support Fixed-Treatment Duration of Imbruvica/Venclexta Combo Could Lead to Treatment Discontinuation in Certain Patients With CLL/SLL

December 5th 2020, 9:07pm

American Society of Hematology Annual Meeting

Data suggest that patients with CLL/SLL who achieve confirmed undetectable minimal residual disease following 12 cycles of Imbruvica combined with Venclexta could possibly discontinue and reasonably remain off treatment.

High-Dose Imetelstat Could Offer Patients with High-Risk Myelofibrosis Improved Overall Survival

High-Dose Imetelstat Could Offer Patients with High-Risk Myelofibrosis Improved Overall Survival

December 5th 2020, 8:00pm

American Society of Hematology Annual Meeting

An analysis of the phase 2 study IMbark shows how imetelstat can offer patients with high-risk myelofibrosis multiple clinical benefits, setting the stage for an expanded phase 3 trial.

CURE®’s 8th Annual MPN Heroes Program Honors ‘Team of Warriors’ Who Have Overcome Challenges in Myeloproliferative Neoplasms

CURE®’s 8th Annual MPN Heroes Program Honors ‘Team of Warriors’ Who Have Overcome Challenges in Myeloproliferative Neoplasms

December 5th 2020, 3:00pm

MPN Heroes®

Five patient advocates, two oncologists and one caregiver were honored during CURE®’s eighth annual MPN Heroes Program.

Evolving Standards and Heated Debates in the Treatment of Newly Diagnosed Multiple Myeloma

Evolving Standards and Heated Debates in the Treatment of Newly Diagnosed Multiple Myeloma

December 4th 2020, 2:00pm

Educated Patient® Multiple Myeloma Summit

Evolving standards of care in newly diagnosed multiple myeloma (MM) have given patients a wider variety of possibilities but can also be disconcerting. In a presentation during CURE®’s Educated Patient® Multiple Myeloma Summit, Dr. Clifton Mo, of Dana-Farber Cancer Institute, explores the treatment landscape and breaks down what these different options can offer patients.

How CAR-T Cell Therapy is Being Used in the Field of Blood Cancer Treatment

How CAR-T Cell Therapy is Being Used in the Field of Blood Cancer Treatment

November 11th 2020, 7:00pm

Educated Patient® Leukemia and Lymphoma Summit

CAR-T cell therapy is a relatively new treatment option for patients with blood cancers, but it’s one showing promise across the landscape. Here’s what you need to know.

Extraordinary Healer® Award for Oncology Nursing 2020

Extraordinary Healer® Award for Oncology Nursing 2020

October 20th 2020, 8:00pm

Extraordinary Healer® Award for Oncology Nursing

View the entire Extraordinary Healer® Award for Oncology Nursing virtual presentation here!

Susan G. Komen Greater New York City 4th Annual Patient Navigation Town Hall Livestream

Susan G. Komen Greater New York City 4th Annual Patient Navigation Town Hall Livestream

June 22nd 2020, 9:08pm

Susan G. Komen Greater New York City Annual Patient Navigation Town Hall

In partnership with CURE®, Susan G. Komen Greater New York City hosts its 4th Annual Patient Navigation Town Hall "Empowering and Mobilizing Our Patient Navigation Workforce". Oncologists, community health workers and patient navigators will get together on June 23rd, via webinar, to discuss the impact of the COVID-19 pandemic on the cancer landscape and how professionals and patients can navigate the fallout moving forward.

Advice for the Newly Diagnosed: How to Play an Active Role in Your Treatment

Advice for the Newly Diagnosed: How to Play an Active Role in Your Treatment

March 28th 2020, 1:00am

Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit

“Often you think we’re the victim, but there’s a lot that you can do to be your own advocate and participate in your healing,” says stage four metastatic breast cancer thriver Nalie Agustin.

Genetic Testing May Offer More Through Clinical Trial Matching

Genetic Testing May Offer More Through Clinical Trial Matching

March 24th 2020, 7:06pm

Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit

Genetic testing offers a care team a wealth of knowledge to help them craft treatments, but it also can help match patients to clinical trials for potentially better outcomes.

Financial Assistance Programs Offer Out-of-Pocket Cost Relief to Patients with Cancer

Financial Assistance Programs Offer Out-of-Pocket Cost Relief to Patients with Cancer

March 24th 2020, 12:15am

Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit

Patients faced with cancer are also faced with tough uphill financial battles, but there are assistance programs that can help.

'Knowledge is Power' in Genetic Testing for Hereditary Cancer

'Knowledge is Power' in Genetic Testing for Hereditary Cancer

March 21st 2020, 12:00am

Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit

Having the right understanding and information of a patient’s genetics can not only help treat cancer but also help prevent it.

A Metastatic Breast Cancer Thriver Shares the Importance of Understanding Your Diagnosis

A Metastatic Breast Cancer Thriver Shares the Importance of Understanding Your Diagnosis

March 20th 2020, 12:00am

Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit

Understanding a diagnosis is not just something for a patient's care team, the patient needs to understand their diagnosis as well.

The Importance of Biomarker Testing for Patients and Their Families

The Importance of Biomarker Testing for Patients and Their Families

March 19th 2020, 1:09am

Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit

Understanding biomarkers specific to breast cancer can guide treatment plans and help families with a history of the disease take preventive measures.

Here's What Patients With Breast Cancer Need to Know About CDK 4/6 Inhibitors

Here's What Patients With Breast Cancer Need to Know About CDK 4/6 Inhibitors

March 18th 2020, 10:00pm

Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit

As CDK 4/6 inhibitors become a bigger part of the treatment of breast cancer, CURE® sat down with clinical nurse specialist Patricia Jakel to discuss the essentials about the drug.

Advice to the Newly Diagnosed: Get a Second Opinion

Advice to the Newly Diagnosed: Get a Second Opinion

March 14th 2020, 10:00pm

Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit

Don’t be worried to get a second opinion — it could save your life.

Utilizing the Patient Perspective as a Patient Advocate

Utilizing the Patient Perspective as a Patient Advocate

March 13th 2020, 10:27pm

Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit

Being a patient with cancer gives you a unique perspective that can become beneficial when serving as an advocate for others.

What to Do After You Hear the Words 'You Have Cancer'

What to Do After You Hear the Words 'You Have Cancer'

March 9th 2020, 10:02pm

Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit

If patients take a deep breath and concentrate on the journey ahead after receiving a diagnosis, they can find a path forward, says one metastatic breast cancer thriver.

Breast Implant-Associated Anaplastic Large Cell Lymphoma: Symptoms, Diagnosis and Treatment

Breast Implant-Associated Anaplastic Large Cell Lymphoma: Symptoms, Diagnosis and Treatment

March 9th 2020, 7:00pm

Miami Breast Cancer Conference and Educated Patient Breast Cancer Summit

At the 37th Annual Miami Breast Cancer Conference, Dr. Valerie Lemaine discussed the signs and symptoms of BIA-ALCL, as well as how the disease is diagnosed and treated.